Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report suggests that lisinopril may cause alopecia, which resolved after the patient switched to losartan potassium.

This study analyzed pexidartinib-associated adverse events from FDA data and reported common events such as hepatic issues and systemic reactions. It highlighted sex-specific susceptibilities and reinforced the need for risk mitigation and long-term monitoring in tenosynovial giant cell tumor management.

This article describes how a new blood glucose management service at the NIH Clinical Center improved safety and patient outcomes for hospitalized patients with diabetes.

This study concluded that alopecia is a rare side effect of SSRIs, with sertraline showing a higher association compared to citalopram, particularly among women.

This article discusses the growing trend of repurposing existing medications for innovative therapeutic uses and highlights the need for pharmacy practitioners to be informed about accessing clinical evidence related to these applications, but it reports no new results.

This case study highlights that even professional eyebrow tinting can lead to chemical burns, and increasing consumer awareness is crucial as its popularity grows and unregulated products become more common.

This study identified numerous drugs with potential to trigger vitiligo, cautioning that these pharmacovigilance findings need further validation and that patients on these medications should be monitored for vitiligo development.

This study identified potential new adverse drug reaction signals for erlotinib, used in lung and pancreatic cancer treatment, by analyzing a large dataset of case reports, indicating further clinical studies are necessary to confirm these findings.

In this study, researchers introduced a visible-light-mediated intramolecular cycloaddition method that selectively forms 6-azabicyclo[3.1.1]heptanes, suggesting these structures could offer promising new scaffolds for drug discovery and medicinal chemistry.

This study found that non-bleeding adverse events associated with NOACs affect multiple organ systems, emphasizing the importance of clinical vigilance. Specific NOACs like dabigatran, apixaban, edoxaban, and rivaroxaban were linked to distinct adverse reactions, including metabolic imbalances, thyroid disorders, and menstrual irregularities.

This study examined data from the FDA Adverse Event Reporting System and found that finasteride use is linked with both known and previously unlisted adverse events, such as erectile dysfunction and post-5α reductase inhibitor syndrome, with variations observed by age and sex.

This study revealed significant signals of drug-related cognitive disorders in several medications that lack relevant FDA label warnings, suggesting a need for increased clinical awareness and potential label updates.

In this study analyzing FDA data, researchers found that tralokinumab was associated with higher reports of conjunctivitis and keratitis compared to dupilumab, while dupilumab had more frequent injection site reactions, highlighting potential risks for clinical monitoring in atopic dermatitis treatments.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This pharmacovigilance study identified 64 drugs linked to hair loss, revealing specific demographic trends and timing patterns, and emphasized the importance of gender-specific monitoring and label updates to better convey real-world risks.

Alopecia areata is relatively common in children, has a variable course, and shows different responses to treatment; thyroid testing is recommended for those affected.

This review examines the direct-to-consumer genetic testing market, highlighting the available tests, regulatory issues, and calls for increased oversight, and reports no new results.

This review discusses the development and potential therapeutic applications of adenosine receptor agonists and positive allosteric modulators, noting that while many clinical trials have been unsuccessful, initial results for new compounds are promising.

This review discusses the development and future prospects of biomaterials for in situ tissue regeneration but reports no new research results; it underscores the importance of biomaterials in addressing tissue defects.

This study identified novel genetic associations with skin phenotypes such as age-spots, freckles, and hair characteristics in Japanese women, providing insights into the genetic basis of these traits.

This study identified novel compounds from Bombax ceiba stem bark, including shamimicin, with potent hypotensive effects, and reported that a specific fraction had adverse effects on heart, liver, and kidneys in mice.

This review discusses the use of platelet lysate and its growth factors in treating diseases and regenerative medicine but reports no new clinical findings.

This review discusses the potential of plant polyphenols to overcome multidrug resistance in various solid cancers and reports no new experimental results; further research is suggested.

This review discusses the role of phytochemical nanoparticles in cervical cancer therapy and reports no new clinical results; the authors highlight their potential advantages over conventional chemotherapy.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

This review discusses the mechanisms and engineering techniques for enhancing the targeted delivery of extracellular vesicles in therapies but reports no new clinical findings; the authors encourage further exploration to advance clinical applications.

This study found that melatonin significantly improved metabolic and reproductive parameters in PCOS-induced rats, with effects similar to metformin.

This review focuses on the immunologic-based skin conditions that can result from β-blocker use, emphasizing potential adverse dermatologic effects rather than their therapeutic benefits.

This review discusses the limited objective evidence for using finasteride in women with alopecia, suggesting that it could be considered for those who don't benefit from minoxidil, but reports no new clinical results.

This review concluded that finasteride may reduce hirsutism scores and hair diameter in women with hyperandrogenism, but concerns about teratogenicity and long-term safety make it a secondary treatment option.